Triple-negative breast cancer (TNBC) poses a serious therapeutic challenge due to the occurrence of frequently aggressive, heterogenic, and metastatic tumours. The absence of therapeutic targets for traditional therapies is a hindrance to establishing a standardised therapy for TNBC. There is limited TNBCs epidemiological and real-world data about TNBC treatment regimens in Poland. We retrospectively analysed clinical data from our hospital registry from 2015 and 2020. A total of 8103 individuals with breast cancer were admitted to the MSCI, while 856 (10.6%) were diagnosed with TNBC. Most of the early-stage or locally advanced TNBC individuals had underlying conditions, presented mostly poorly differentiated (G3) stage II tumours and featured a bi-modal age distribution. On average, one-third of all tested TNBCs carriedBRCAmutations and its identification impacted surgery preference. We observed a significant increase in the use of systemic therapy among TNBCs, whereas carboplatin and dose-dense regimens showed the most prominent upsurge in the neoadjuvant setting. Moreover, the use of neoadjuvants was positively correlated with less invasive breast and lymph node surgeries. The presented data align with general trends observed in other countries and will contribute to expanding knowledge in the planning of treatment regimens and their outcomes.
三阴性乳腺癌因其肿瘤常具有侵袭性强、异质性高及易转移的特性，构成了严峻的治疗挑战。传统疗法缺乏有效的治疗靶点，阻碍了三阴性乳腺癌标准化治疗方案的建立。目前波兰关于三阴性乳腺癌治疗方案流行病学及真实世界数据的研究较为有限。本研究回顾性分析了2015年至2020年本院登记系统的临床数据。期间玛丽亚·斯克沃多夫斯卡-居里肿瘤研究所共收治8103例乳腺癌患者，其中856例（10.6%）确诊为三阴性乳腺癌。多数早期或局部晚期三阴性乳腺癌患者伴有基础疾病，肿瘤分级以低分化（G3）II期为主，年龄分布呈现双峰特征。平均约三分之一受检三阴性乳腺癌携带BRCA基因突变，该检测结果对手术方案选择产生影响。我们观察到三阴性乳腺癌全身治疗使用率显著上升，其中新辅助治疗中卡铂及密集剂量方案的增长尤为显著。此外，新辅助治疗的应用与创伤更小的乳腺及淋巴结手术呈正相关。本研究数据与其他国家观察到的总体趋势一致，将为拓展治疗方案规划及其疗效评估的知识体系提供参考。
肿瘤(癌症)患者之家